This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
In what one analyst called a “unique situation,” the company stopped dosing pati...
“There is not a single member of AAM who has not raised concerns about the tarif...
Antibody-drug conjugates (ADCs) are revolutionizing oncology, but success requir...
Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter...
The pharmaceutical giant named Jeffrey Legos the head of a division it is counti...
Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of ...
The drugmaker’s financial forecasts topped Wall Street’s expectations, reassurin...
The pharmaceutical company plans to cut $2 billion in annual expenses by the end...
The biotech is evaluating several cystic fibrosis medicines that could either wo...
The two biotechs, which have lost most of their share value following lucrative ...
The investment firm is acquiring Mitsubishi Tanabe Pharma in a deal valued at $3...
Elsewhere, cell therapy developer Turnstone Biologics announced a second round o...
CagriSema, which underperformed expectations in its first Phase 3 test, will be ...